Salud financiera de hoja de balance de Active Biotech

Salud financiera controles de criterios 3/6

Active Biotech tiene un patrimonio de los accionistas total de SEK1.4M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK14.9M y SEK13.5M respectivamente.

Información clave

Ratio deuda-patrimonio

SEK 0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	SEK 6.20m
Patrimonio	SEK 1.40m
Total pasivo	SEK 13.50m
Activos totales	SEK 14.90m

Actualizaciones recientes sobre salud financiera

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Jun 05

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03

Recent updates

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Jun 05

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Feb 19

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Jul 27

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

May 07

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Jan 18

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK10.7M) de ACTI no cubren sus pasivos a corto plazo (SEK11.5M).

Pasivo a largo plazo: Los activos a corto plazo de ACTI (SEK10.7M) superan a sus pasivos a largo plazo (SEK2.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ACTI está libre de deudas.

Reducción de la deuda: ACTI no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ACTI tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: ACTI tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 5.3% cada año

Salud financiera de hoja de balance de Active Biotech

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

Recent updates

New major risk - Financial position

New major risk - Market cap size

New minor risk - Share price stability

Active Biotech AB (Publ) Reports Intention Inaugural Interocular Concentrations Achieves in A Clinical Bylistribution Study of Laquinimod Eye Drops

No longer forecast to breakeven

Active Biotech Provides Update on the Clinical Phase Ib/IIa Study with Tasquinimod in Relapsed Refractory Multiple Myeloma

Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Active Biotech AB (publ) Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Active Biotech AB (publ), Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Active Biotech AB (Publ) Provides Update on the Scheduled Clinical Program for 2024

Active Biotech AB (Publ) Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee

Forecast breakeven date pushed back to 2025

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Forecast to breakeven in 2024

Active Biotech AB (publ) Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

New major risk - Share price stability

Insufficient new directors

Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma

Active Biotech AB (Publ) Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops

Active Biotech AB (publ) to Report First Half, 2023 Results on Aug 24, 2023

Active Biotech's Announces Nomination Committee

Forecast to breakeven in 2024

Active Biotech AB (publ) to Report Fiscal Year 2022 Results on Feb 09, 2023

Active Biotech AB (Publ) Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage

Active Biotech AB (publ) announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Price target decreased to kr2.50

High number of new and inexperienced directors

Active Biotech AB (publ) to Report Q3, 2022 Results on Nov 03, 2022

Active Biotech Announces First Patient Dosed in the Combination Part of the Phase Ib/IIa Study of Tasquinimod in Multiple Myeloma

Active Biotech AB (publ) Announces First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Active Biotech AB (publ) Provides Status Update of its Clinical Naptumomab Project

Independent Director recently bought kr60k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Active Biotech Receive Milestone Payment from Neotx

New 90-day low: kr1.44

Active Biotech AB Appoints Elaine Sullivan as A Director

New 90-day low: kr1.50

New 90-day low: kr1.98

New 90-day low: kr2.15

New 90-day low - kr2.48

Earnings released

New 90-day high - kr2.88

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera